Targeting protein tyrosine phosphatases for anticancer drug discovery.
Targeting protein tyrosine phosphatases for anticancer drug discovery.
复制标题
DOI：
10.2174/138161210791209027
复制
发表时间：
2010-06
影响因子：
3.1
通讯作者：
Wu J
中科院分区：
文献类型：
--
作者：
Scott LM;Lawrence HR;Sebti SM;Lawrence NJ;Wu J
蛋白酪氨酸磷酸酶 (PTP) 是由人类基因组中 107 个基因编码的多样化酶家族。 PTP 与蛋白酪氨酸激酶 (PTK) 一起调节对于恶性表型的启动和维持至关重要的各种细胞活动。虽然 PTK 抑制剂现已常规用于癌症治疗，但 PTP 抑制剂开发领域仍处于发现阶段。在本文中，讨论了靶向 PTP 在新型抗癌药物发现中的适用性。提供了用于抗癌药物发现的 PTP 的示例，以及用于新型抗癌药物发现的潜在新 PTP 靶点。
Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.